- Conditions
- Cardiovascular Diseases, Hypertension
- Interventions
- Williams LifeSkills Stress and Anger Management Workshop, High school classes
- Behavioral
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 14 Years to 18 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 75
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertension
- Interventions
- Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 11,506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Interventions
- JK07
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Stage 2 Systolic Hypertension
- Interventions
- valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Hypertension, Aging
- Interventions
- Nicotinamide riboside, Placebo
- Drug · Other
- Lead sponsor
- Douglas Seals
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Hypertension
- Interventions
- Valsartan + HCTZ, Valsartan, HCTZ
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more
- Conditions
- Hypertension, Pulmonary, Ventricular Dysfunction, Left
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Diego, California • Torrance, California + 11 more
- Conditions
- Hypertension, Hypotension
- Interventions
- Not listed
- Lead sponsor
- Sotera Wireless, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Systolic Hypertension, Brachial Artery Flow-mediated Dilation
- Interventions
- POWERbreathe K5
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hypertension
- Interventions
- Nebivolol, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 36
- States / cities
- Foley, Alabama • Montgomery, Alabama • Chino, California + 30 more
- Conditions
- Hypertension
- Interventions
- Valsartan, Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Blood Pressure, Endothelial Dysfunction, Hypertension
- Interventions
- Inspiratory muscle strength training, Brisk walking
- Other
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Hypertension
- Interventions
- Nebivolol
- Drug
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypertension
- Interventions
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Hypertension
- Interventions
- Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Renal Artery Stenosis, Hypertension, Renovascular
- Interventions
- iCAST™ Rx Stent System
- Device
- Lead sponsor
- Atrium Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 12
- States / cities
- Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more
- Conditions
- Cardiovascular Disease
- Interventions
- ALT-711 (alagebrium chloride)
- Drug
- Lead sponsor
- Synvista Therapeutics, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
- Interventions
- grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hypertension, Systolic, Stiffness, Aortic
- Interventions
- Clonidine, Hydrochlorothiazide, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Hypertension
- Interventions
- Aliskiren Hydrochlorothiazide, Ramipril
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more
- Conditions
- Hypertension
- Interventions
- Aliskiren
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 19
- States / cities
- Orangevale, California • Brooklyn Center, Minnesota • Butte, Montana + 16 more
- Conditions
- Hypertension
- Interventions
- valsartan + amlodipine
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Hypertension
- Interventions
- Low-fat dairy
- Other
- Lead sponsor
- Dairy Research Institute
- Other
- Eligibility
- 20 Years to 69 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Glen Ellyn, Illinois
- Conditions
- Hypertension
- Interventions
- Intensive control of SBP, Standard control of SBP
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 9,361 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina